Back to Search Start Over

Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes:A Nationwide Study and Meta-analysis

Authors :
Israelsen, Simone Bastrup
Ernst, Martin Thomsen
Lundh, Andreas
Lundbo, Lene Fogt
Sandholdt, Håkon
Hallas, Jesper
Benfield, Thomas
Israelsen, Simone Bastrup
Ernst, Martin Thomsen
Lundh, Andreas
Lundbo, Lene Fogt
Sandholdt, Håkon
Hallas, Jesper
Benfield, Thomas
Source :
Israelsen , S B , Ernst , M T , Lundh , A , Lundbo , L F , Sandholdt , H , Hallas , J & Benfield , T 2021 , ' Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes : A Nationwide Study and Meta-analysis ' , Clinical Gastroenterology and Hepatology , vol. 19 , no. 9 , pp. 1845-1854.e6 .
Publication Year :
2021

Abstract

Background & Aims: Proton pump inhibitor (PPI) use has been associated with increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe outcomes. However, meta-analyses show unclear results, leading to uncertainty regarding the safety of PPI use during the ongoing coronavirus disease 2019 (COVID-19) pandemic. Methods: We conducted a nationwide observational study including all SARS-CoV-2 cases (n = 83,224) in Denmark as of December 1, 2020. The association of current PPI use with risk of infection was examined in a case-control design. We investigated the risk of severe outcomes, including mechanical ventilation, intensive care unit admission, or death, in current PPI users (n = 4473) compared with never users. Propensity score matching was applied to control for confounding. Finally, we performed an updated meta-analysis on risk of SARS-CoV-2 infection and COVID-19 mortality attributable to PPI use. Results: Current PPI use was associated with increased risk of infection; adjusted odds ratio, 1.08 (95% confidence interval [CI], 1.03–1.13). Among SARS-CoV-2 cases, PPI use was associated with increased risk of hospital admission; adjusted relative risk, 1.13 (1.03–1.24), but not with other severe outcomes. The updated meta-analysis showed no association between PPI use and risk of infection or mortality; pooled odds ratio, 1.00 (95% CI, 0.75–1.32) and relative risk, 1.33 (95% CI, 0.71–2.48). Conclusions: Current PPI use may be associated with an increased risk of SARS-CoV-2 infection and hospital admission, but these results with minimally elevated estimates are most likely subject to residual confounding. No association was found for severe outcomes. The results from the meta-analysis indicated no impact of current PPI use on COVID-19 outcomes.

Details

Database :
OAIster
Journal :
Israelsen , S B , Ernst , M T , Lundh , A , Lundbo , L F , Sandholdt , H , Hallas , J & Benfield , T 2021 , ' Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes : A Nationwide Study and Meta-analysis ' , Clinical Gastroenterology and Hepatology , vol. 19 , no. 9 , pp. 1845-1854.e6 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1322769643
Document Type :
Electronic Resource